SRX246 clinical trials
Also written SRX246.
How each study uses SRX246 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the SRX246 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- SRX246
- 7
Studies by the year they started
7 studies that test it; most in 2016 (2)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2010 | 1 |
| 2014 | 1 |
| 2016 | 2 |
| 2017 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Azevan Pharmaceuticals (7)
Studies
Open first, then newest update. How each study uses SRX246 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Inhibition of Aggressive Behavior in Participants With Fragile X SyndromeNot yet recruitingPhase 2Azevan PharmaceuticalsNCT07328529Written as SRX246
- Safety, Tolerability and Activity of SRX246 in Adults With Intermittent Explosive DisorderCompletedPhase 1/2Azevan PharmaceuticalsNCT02055638Written as SRX246
- Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's DiseaseCompletedPhase 2Azevan PharmaceuticalsNCT02507284Written as SRX246
- Proof-of-concept Study to Assess the Efficacy and Safety of SRX246 in Adults With PTSDTerminatedPhase 2Azevan PharmaceuticalsNCT02733614Written as SRX246
- Effects of SRX246 on an Experimental Model of Fear and Anxiety in HumansStatus unknownPhase 1Azevan PharmaceuticalsNCT02922166Written as SRX246
- Multiple Dose Safety Study of SRX246 Capsules in Healthy VolunteersCompletedPhase 1Azevan PharmaceuticalsNCT01088932Written as SRX246
- Study of SRX246 Capsules in Healthy Adult VolunteersCompletedPhase 1Azevan PharmaceuticalsNCT00910455Written as SRX246
Codes
What other systems call SRX246 · ClinicalTrials.gg INT006384
- MeSH (NLM) C584649SRX246One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C584649 | SRX246 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.